Spinal Muscular Atrophy Market: Navigating Therapeutic Advances towards USD 5.6 Billion by 2034, with a CAGR of 14.80% - By PMI
15 févr. 2024 17h02 HE
|
PMI
Covina, Feb. 15, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Spinal Muscular Atrophy Market size was valued at about USD 1.4 Billion in 2024 and expected to grow at CAGR of...
Spinal Muscular Atrophy Market to Grow Rapidly During the Forecast Period (2019–2032), Assesses DelveInsight | Key Players - Biogen, NMD Pharma, Novartis, Roche, Biohaven Pharmaceuticals, Scholar Rock, AnnJi Pharmaceutical
31 oct. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Spinal Muscular Atrophy Market to Grow Rapidly During the Forecast Period (2019–2032), Assesses DelveInsight | Key Players - Biogen, NMD Pharma,...
Spinal Muscular Atrophy Treatment Market to Reach $8.4Billion, Globally, by 2032 at 6.8% CAGR: Allied Market Research
18 juil. 2023 10h00 HE
|
Allied Market Research
Portland, OR, July 18, 2023 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, “Spinal Muscular Atrophy Treatment Market By Type (Type 1, Type 2, and Others), By Route of...
Muscular Dystrophy Association Announces 2023 National Ambassador Leah Zelaya from New York
23 janv. 2023 10h00 HE
|
Muscular Dystrophy Association
New York, NY, Jan. 23, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) has selected 15-year-old Leah Zelaya from Brooklyn, New York, as its 2023 MDA National Ambassador. ...
NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3
14 déc. 2022 07h00 HE
|
NMD Pharma
NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3 Aarhus, Denmark, 14 December 2022 – NMD Pharma A/S, a...
NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3
14 déc. 2022 01h00 HE
|
NMD Pharma
NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3 Aarhus, Denmark, 14 December 2022 – NMD Pharma A/S, a...
Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases
01 mai 2019 07h30 HE
|
Biogen Inc.
Data demonstrate that pre-symptomatic infants with SMA treated with SPINRAZA® (nusinersen) over three years achieved motor milestones that are more consistent with normal childhood...
La réaction de Biogen aux recommandations mises à jour de l’ACMTS concernant l’accès à SPINRAZA
01 mars 2019 20h18 HE
|
Biogen Canada
·L’Agence canadienne des médicaments et des technologies de la santé (ACMTS) a élargi ses recommandations concernant le financement par les fonds publics du traitement des patients atteints...
Biogen Responds to CADTH’s updated recommendation regarding coverage for SPINRAZA
01 mars 2019 20h18 HE
|
Biogen Canada
·Canadian Association of Drugs and Technologies in Health (CADTH) has expanded their recommendations for public reimbursement for SMA patients ·The recommendation, however, continues to limit access...
Global CNS Specific Antisense Oligonucleotide Market to Surpass US$ 6.8 Billion by 2026 – Coherent Market Insights
08 févr. 2019 08h30 HE
|
CMI
SEATTLE, Feb. 08, 2019 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global CNS specific antisense oligonucleotide market is valued at US$ 883.7 million in 2017, and is projected to...